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ABSTRACT  
Increased permeability of the blood-brain barrier (BBB) is important in neurological disorders. 
Neuroinflammation is associated with increased BBB breakdown and brain injury. Tumor necrosis factor-α 
(TNF-α) is involved in BBB injury and edema formation through a mechanism involving matrix 
metalloproteinase (MMP) upregulation. There is emerging evidence indicating that cyclooxygenase (COX) 
inhibition limits BBB disruption following ischemic stroke and bacterial meningitis, but the mechanisms 
involved are not known. We used intracerebral injection of TNF-α to study the effect of COX inhibition on 
TNF-α-induced BBB breakdown, MMP expression/activity and oxidative stress. BBB disruption was 
evaluated by the uptake of 14C-sucrose into the brain and by magnetic resonance imaging (MRI) utilizing 
Gd-DTPA as a paramagnetic contrast agent. Using selective inhibitors of each COX isoform, we found that 
COX-1 activity is more important than COX-2 in BBB opening. TNF-α induced a significant upregulation of 
gelatinase B (MMP-9), stromelysin-1 (MMP-3) and COX-2. In addition, TNF-α significantly depleted 
glutathione as compared to saline. Indomethacin (10 mg/kg; i.p.), an inhibitor of COX-1 and COX-2, 
reduced BBB damage at 24 h. Indomethacin significantly attenuated MMP-9 and MMP-3 expression and 
activation, and prevented the loss of endogenous radical scavenging capacity following intracerebral 
injection of TNF-α. Our results show for the first time that BBB disruption during neuroinflammation can be 
significantly reduced by administration of COX inhibitors. Modulation of COX in brain injury by COX 
inhibitors or agents modulating prostaglandin E2 formation/signaling may be useful in clinical settings 
associated with BBB disruption. 
 
INTRODUCTION  
Increased permeability of the BBB is a pathological hallmark in several neurological disorders (Hawkins 
and Davis, 2005). Neuroinflammatory events are associated with increased BBB breakdown and brain 
injury. Tumor necrosis factor-α (TNF-α) has been demonstrated to participate in the BBB opening, which 
follows cerebral ischemic injury (Yang et al., 1999), sepsis (Tsao et al., 2001), bacterial meningitis (Ramilo 
et al., 1990), and human immunodeficiency virus type-1 (HIV-1) infection (Fiala et al., 1997). TNF-α-
mediated BBB breakdown is linked to the upregulation of matrix metalloproteinase (MMP) expression and 
activity (Rosenberg et al., 1995b). 
 
Metabolism of arachidonic acid through cyclooxygenase (COX) plays a key role in neuroinflammatory 
events (Hewett et al., 2006). COX inhibition effectively blocked BBB permeability increases induced by 
TNF-α in an in vitro model of BBB using bovine brain microvessel endothelial cells (BBMECs) (Mark et al., 
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2001c). They showed that the increased permeability and cytoskeletal structural changes observed in the 
BBMECs following exposure to TNF-α involved the induction of COX-2 with increased release of 
prostaglandins (Mark et al., 2001b). Prostaglandin E2 (PGE2), the major prostanoid produced by COX 
activity in the brain, produced marked BBB breakdown when administered intracerebrally in the rat 
(Schmidley et al., 1992). Selective COX-2 inhibition with NS-398 reduced the effects of TNF-α on 
cerebromicrovascular permeability in a rat cranial window model (Trickler et al., 2005). Furthermore, COX 
inhibition with indomethacin significantly reduced BBB disruption induced by TNF-α in vitro (de Vries et al., 
1996).  
 
COX inhibition reduces the expression of MMP-2 and MMP-9 in human monocytes (Cipollone et al., 2005), 
macrophages (Pavlovic et al., 2006), and several tumor cell lines (Pan et al., 2001; Kinugasa et al., 2004). 
Additionally, COX inhibition has been proven to reduce oxidative stress during neuroinflammation 
(Candelario-Jalil et al., 2003d; Akundi et al., 2005b), which might also contribute to the reduction of MMP 
expression and activity seen in peripheral cells. We recently showed that the COX-2 inhibitor, nimesulide, 
reduces BBB damage and leukocyte infiltration following focal cerebral ischemia (Candelario-Jalil et al., 
2007b). However, the precise molecular mechanism(s) through which COX inhibition limits BBB opening, 
and its possible relation to MMP expression/activity, had not been previously investigated.  
 
In the study presented here, we utilized a well-characterized animal model of TNF-α-induced BBB 
disruption to investigate the effects of COX inhibition on MMP expression and activity. By using selective 
inhibitors of COX-1 and COX-2, we studied the relative contribution of each isoform to TNF-α-mediated 
BBB opening. We showed that COX-1 selective inhibition or inhibition of both isozymes with indomethacin 
significantly reduced BBB damage in this model of neuroinflammation, as assessed by the 14C-sucrose 
uptake method and corroborated by MRI permeability measurements (Sood et al., 2007a). Inhibition of 
COX with indomethacin reduced the significant increase in MMP-3 and MMP-9 expression/activity and 
prevented the loss of endogenous antioxidant capacity induced by TNF-α. Our present results indicate that 
COX is important in BBB permeability changes induced by TNF-α. Upregulation of MMPs and increase in 
oxidative stress link COX activity to BBB disruption.  
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MATERIALS AND METHODS 
Stereotaxic Surgery and Intracerebral Administration of TNF-α in the Rat  
All animal studies were approved by the University of New Mexico Health Sciences Center’s Animal Care 
and Use Committee and conformed to NIH guidelines for use of animals in research. Male Wistar rats 
(Harlan, Indianapolis, IN) weighing 280-320 g were used in this study. Animals were anesthetized with 
1.5% halothane in 70% nitrous oxide and 30% oxygen. Rats were then positioned in a stereotaxic 
headholder (Kopf Instruments, Tujunga, CA) and a burr hole was made in the skull 3 mm lateral from 
midline, at bregma. Intrastriatal injections of rhTNF-α (5000 U of recombinant human TNF-α; Upstate, Lake 
Placid, NY) in 10 μl of sterile physiological saline (Hospira Inc., Lake Forest, IL) were administered 5 mm 
below the dura over a 10 min duration with a microsyringe (Hamilton, Reno, NV). The needle was left in 
place another 3 minutes. Evan’s blue dye was added to the infusate for localization of the injection site. The 
burr hole was sealed with bone wax and the skin incision was closed with 4-0 silk sutures.  
 
Evaluation of BBB Permeability with 14C-Sucrose 
Opening of the BBB induced by TNF-α was evaluated using the sucrose space method, as described in 
detail previously (Rosenberg et al., 1998a). Briefly, animals were anesthetized and infused through the 
femoral vein with 10 μCi of 14C-sucrose (molecular mass 342 Da; PerkinElmer, Waltham, MA). Ten minutes 
later, a sample of blood was drawn from the femoral vein, and animals were sacrificed with an intracardiac 
injection of a saturated KCl solution. Brains were rapidly removed and frozen in 2-methylbutane cooled to -
80°C in liquid nitrogen. For evaluating the BBB breakdown, striata and overlying cortex were dissected out 
for regional evaluation of BBB opening. Tissues were dissolved in Solvable (DuPont, Boston, MA) and 14C-
sucrose was measured in both brain samples and plasma in a liquid scintillation counter (Beckman LS6500 
Scintillation Counter; GMI Inc., Ramsey, MN) using CytoScint as the liquid scintillation cocktail (ICN 
Biomedicals, Costa Mesa, CA). Ratios were used to calculate brain sucrose uptake as an estimate of 
capillary permeability (Rosenberg et al., 1998b). 
 
Gelatin-Substrate Zymography 
For zymography, tissues were homogenized in a lysis buffer containing 50 mM Tris-HCl pH 7.6, 150 mM 
NaCl, 5 mM CaCl2, 0.05% Brij-35, 1% Triton X-100, and 0.02% NaN3. Protein concentration in the 
homogenate was determined using the Micro BCA Protein Assay kit (Pierce, Rockford, IL). MMP-2 and 
MMP-9 present in the homogenates were concentrated with Gelatin-Sepharose 4B beads (GE Healthcare 
Biosciences, Piscataway, NJ), and analyzed by gelatin zymography as previously described (Zhang and 
Gottschall, 1997). Briefly, 800 μg of total protein in 500 μl was incubated with 80 μl of Gelatin-Sepharose 
4B beads for 1 h at 4°C with gentle agitation. The beads were collected and the gelatinases were eluted by 
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incubating with 80 μl of elution buffer (10% DMSO in phosphate buffered saline) for 30 min at 4°C with 
gentle shaking. Equal amount of samples (20 μl) were mixed in a loading buffer containing 80 mM Tris-HCl 
pH 6.8, 4% sodium dodecyl sulfate (SDS), 10% glycerol, and 0.01% bromophenol blue. Samples were 
electrophoretically separated on 10% SDS-polyacrylamide gels co-polymerized with 1 mg/ml gelatin 
(Sigma-Aldrich, St. Louis, MO) under non-reducing conditions. Gels were washed in 2.5% Triton X-100 and 
then incubated for 40 h at 37°C in a developing buffer containing 50 mM Tris pH 7.6, 5 mM CaCl2, 0.2 mM 
NaCl, and 0.02% Brij-35. After incubation, gels were stained with 0.125% Coomassie Brilliant Blue R-250 
(Sigma-Aldrich, Saint Louis, MO) for 30 min in 10% acetic acid and 50% methanol. Gels were destained 
with a solution containing 10% acetic acid and 10% methanol until clear bands of gelatinolysis appeared on 
a dark blue background. To confirm that detected activities were zinc-dependent gelatinases, some 
zymogram gels were incubated with developing solution in the presence of 10 mM EDTA. Disappearance 
of lytic bands in these gels confirmed the metal dependence of gelatinolytic activity characteristic of MMPs. 
The gels were dried and densitometrically scanned (Alpha ImagerTM 2200; Alpha Innotech, San Leandro, 
CA). Molecular weights were determined by both protein standards (Bio-Rad Laboratories, Hercules, CA), 
and conditioned media from HT1080 human fibrosarcoma cells, a well-known source of MMP-2 and -9. In 
addition, a mixture of active MMP-2 and -9 standards (Chemicon International, Temecula, CA) were used 
as gelatinase controls. Data were expressed as relative lysis units.  
 
Immunoblotting  
We added to part of the homogenate prepared for zymography complete protease inhibitor cocktail (Roche 
Diagnostics GmbH, Mannheim, Germany). Before electrophoresis, samples (60 μg of total protein) were 
mixed 1:1 with Laemmli sample buffer (65 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 0.002% 
bromophenol blue) containing 5% of 2-mercaptoethanol. Samples were incubated at 100°C for 10 min and 
subjected to SDS-PAGE on a 7.5% gel (for MMP-9, MMP-2 and COX-2) or 10% gel (for MMP-3 and COX-
1) under reducing conditions. Proteins were then transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Millipore, Bedford, MA) by wet blotting. The membrane was blocked for 1 h at room 
temperature with 5% skim milk in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBST) before 
incubation with the primary antibody. Primary polyclonal antibodies were rabbit anti-MMP-9 (AB19016; 
Chemicon International, Temecula, CA; 1:1500), rabbit anti-MMP-2 (sc-10736; Santa Cruz Biotechnology, 
Santa Cruz, CA; 1:200), rabbit anti-COX-2 (160126; Cayman Chemical, Ann Arbor, MI; 1:200), rabbit anti-
COX-1 (160109; Cayman Chemical, Ann Arbor, MI; 1:2000) and goat anti-MMP-3 (ab18898; Abcam, 
Cambridge, MA; 1 μg/ml). Antibody dilutions were made in 5% milk dissolved in TBST. Membranes were 
incubated overnight at 4°C with the corresponding primary antibody. After extensive washing (three times 
for 15 min each in TBST), proteins were detected with horseradish peroxidase (HRP)-linked goat anti-
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rabbit IgG (#7074; Cell Signaling, Danvers, MA; 1:2000) or donkey anti-goat IgG (705-035-147; Jackson 
ImmunoResearch Laboratories, West Grove, PA; 1:10,000) using SuperSignal® West Pico 
Chemiluminescent substrate (Pierce, Rockford, IL). Each blot was stripped and reprobed with a rabbit anti-
actin IgG (Sigma-Aldrich, Saint Louis, MO; 1:7500) to confirm equal protein loading and transfer. 
Quantification of the Western blots was performed using ImageJ software (National Institutes of Health; 
Bethesda, MD). 
 
Tissue Processing for Immunohistochemistry 
Twenty four hours after rhTNF-α or saline injection, rats were anesthetized with pentobarbital (50 mg/kg; 
i.p.), and transcardially perfused with cold phosphate buffered saline (PBS) followed by 2% PLP (2% 
paraformaldehyde, 0.1 M sodium periodate, 75 mM lysine in 100 mM sodium phosphate buffer at pH 7.4). 
Brains were removed and immersed in 2% PLP overnight. The brains were cryoprotected in 30% sucrose 
in 2% PLP, placed in a Peel-A-Way® histology mold (Ted Pella Inc., Redding, CA) containing Tissue-Tek® 
embedding medium (Sakura Finetek, Torrance, CA), and frozen with 2-methylbutane cooled in liquid 
nitrogen. Brains were stored at -80°C until sectioned. Tissue was sectioned on a cryostat (Richard-Allan 
Scientific, Kalamazoo, MI), and SuperFrost®/Plus slides (Fisher Scientific, Pittsburgh, PA) with 10 μm 
sections (5 sections per slide) were stored at -20°C until immunostaining was performed. 
 
Double Immunofluorescence Labeling and Confocal Microscopy 
Immunolabeling was performed for MMP-9, COX-2 and MMP-3. For investigating the cell types expressing 
each of these proteins following rhTNF-α injection, double immunolabeling was performed with specific cell 
markers, including glial fibrillary acidic protein (GFAP; marker of reactive astrocytes), neuron-specific 
nuclear protein (NeuN; marker of neurons) and OX-42 (also known as CD11b; marker of 
microglia/macrophages). Primary antibodies and dilutions used in the immunohistochemical analysis were: 
rabbit anti-MMP-9 (AB19016; Chemicon International, Temecula, CA; 1:300), rabbit anti-COX-2 (160126; 
Cayman Chemical, Ann Arbor, MI; 1:700), rabbit anti-MMP-3 (AB810; Chemicon International, Temecula, 
CA; 1:1000), mouse anti-GFAP (G3893; Sigma-Aldrich, Saint Louis, MO; 1:400), mouse anti-NeuN (MAB-
377; Chemicon International, Temecula, CA; 1:400), and mouse anti-OX-42 (MAS370p; Accurate Chemical 
Corp., Westbury, NY; 1:100). Secondary antibodies and dilutions were: goat anti-rabbit linked to orange-
fluorescent Alexa Fluor® 546 dye (Cy3 filter) and goat anti-mouse labeled with Alexa Fluor® 488 dye (FITC 
filter). Both secondary antibodies were obtained from Invitrogen (Carlsbad, CA) and diluted 1:500.  
 
Double Immunofluorescence was performed as previously described (Yang et al., 2007). Briefly, slides 
were dried for 30 min at 50°C followed by incubation with cold acetone for 5 min. This was followed by two 
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washes in PBS containing 0.1% Tween-20 (PBST). Nonspecific binding sites were blocked for 1 h at room 
temperature with PBST containing 1% bovine serum albumin (BSA; Sigma-Aldrich, Saint Louis, MO) and 
5% normal goat serum (Invitrogen, Carlsbad, CA). Slides were incubated overnight at 4°C with primary 
antibodies. The next day, slides were washed three times in PBST and then incubated for 90 min at room 
temperature with secondary antibodies. Slides were placed in a 50 mM NH4Cl solution for 10 min to reduce 
non-specific fluorescence background. In some experiments, slides were incubated with 4’-6-diamidino-2-
phenylinidole (DAPI) (Invitrogen, Carlsbad, CA) prior to coverslipping to label cell nuclei. Negative controls 
were incubated without the primary antibodies or with normal (non-immune) IgGs from the host species of 
the primary antibodies and failed to exhibit specific immunolabeling (not shown). All slides were viewed on 
an Olympus BX-51 fluorescence microscope (Olympus America Inc., Center Valley, PA) equipped with an 
Optronics digital camera and Picture Frame image capture software (Optronics, Goleta, CA). Dual 
immunofluorescence slides were also imaged confocally to verify co-labeling in a laser scanning confocal 
microscope (Zeiss LSM 510, Carl Zeiss Microimaging Inc., Thornwood, NY).  
 
Magnetic Resonance Imaging (MRI)  
For the MRI study, 8 rats were randomly divided into two groups: the first group consisting of 4 rats that 
received stereotaxic injection of rhTNF-α and treatment with indomethacin, while the second group of rats 
were injected with rhTNF-α, but instead, were treated with the vehicle (n=4). After 24 h, rats were 
transported to the MRI room, placed in a dedicated rat holder and moved to the isocenter of the magnet 
prior to the imaging session. MR imaging was performed on a 4.7T Biospec® dedicated research MR 
scanner (Bruker Biospin, Billerica, MA), equipped with 500 mT/m (rise time 80-120 μs) gradient set (for 
performing small animal imaging) and a small bore linear RF coil (ID 72 mm) (Sood et al., 2007b). Initial 
localizer images were acquired using the following parameters: 2D FLASH (Fast Low Angle SHot), TR/TE 
10/3 ms, matrix 256 x 128, FOV 6.4 cm, 1 slice per orientation. After the localizer images were acquired, 
T2 weighted and diffusion weighted imaging (DWI) was performed with the following parameters; T2 
weighted-2D RARE (Rapid Acquisition with Relaxation Enhancement), TR/TE 4000/65 ms, FOV 3.2 cm x 
3.2 cm, slice thickness 2 mm, slice gap 1 mm, number of slices 2, matrix 256 x 128, number of averages 5, 
receiver bandwidth 100 kHz; DWI - 2D Diffusion weighted RARE, TR/TE 2000/31.2 ms, FOV 3.2 cm x 3.2 
cm, slice thickness 2 mm, slice gap 1 mm, number of slices 2, matrix 64 x 64, number of averages 5, 
receiver bandwidth 100 kHz, d = 5 ms, D= 20 ms, b value of 0 and 900 s mm-2, diffusion gradient along the 
slice select direction.  
 
The slices containing the lesion were identified from the T2 weighted structural images and same slice 
location was prescribed for all the subsequent MR protocols. MR data for generating T2 maps was 
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acquired using the following parameters: 2D MSME (Multi Slice Multi Echo), TR 3000, TE1 30 ms, TE2 60 
ms, TE3 90 ms, TE4 120 ms, FOV 3.2 cm x 3.2 cm, slice thickness 2 mm, slice gap 1 mm, number of 
slices 2, matrix 64 x 64, number of averages 4, receiver bandwidth 100 kHz.  
 
The MR protocol for acquiring data for the Patlak plot method was then implemented (Patlak et al., 1983). 
In this acquisition, a reference baseline acquisition using the fast T1 mapping protocol was obtained. Rats 
were injected 0.2 mmol/kg of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA, MW= 938 Da; 
Berlex, Montville, NJ) as a bolus into the femoral vein via an indwelling catheter, followed by imaging with 
rapid T1 mapping protocol, collecting 14 images over 45 minutes. The following optimized MR imaging 
parameters were used for this protocol: axial plane, 2D IR-SE-EPI, TR/TE 8s/19.4 ms, FOV 4.0 cm x 4.0 
cm, slice thickness 2 mm, slice gap 1 mm, number of slices 2, matrix 64 x 64, number of averages 2, 
receiver bandwidth 250 kHz. Non slice selective magnetization inversion was performed using a hyperbolic 
secant (sech) RF pulse with pulse width 4 ms. The T1 mapping specific parameters for this protocol were; 
time for inversion (TI) TI = (100 + 600 x n) ms where n = 0, 1, 2, …12, number of TI points (n) is 13. The 
total scan time was 3 minutes and 12 seconds for each time point. The MR protocol parameters for rapid 
T1 mapping were optimized for accuracy of T1 relaxation time estimate in a single, normal rat brain 
(control) prior to including that animal in the study. The acquired data were transferred to a dedicated 
computer workstation for post processing. Post processing of the raw data involved generating Apparent 
Diffusion Coefficient (ADC) maps from DWI images, T2 maps, T1 maps from the raw data, reconstruction 
of permeability coefficient maps and construction of the Patlak plots.  
             
All the data processing was performed using in-house software written in 64-bit MATLAB (Mathworks, 
Natick, MA) and implemented on a 64-bit processor (AMD64) workstation running Red Hat Enterprise 
Linux v3 (64-bit). Image analysis was performed using ImageJ (NIH, Bethesda, MD) and MRVision 
(Winchester, MA) software. T2 maps are gray scale images with pixel signal intensity values proportional to 
T2 relaxation times and shades of gray scaled to corresponding pixel-wise T2 values. A region of Interest 
(ROI) was drawn on T2 and ADC maps around the lesion on the ipsilateral side (TNF-α injected) and a 
similar ROI was drawn on the contralateral (normal) side. In the permeability coefficient maps 
reconstructed using MRI data, pixel signal intensity values are proportional to permeability coefficient 
values. Pixels with high and low signal intensity correspond to pixels with high and low permeability 
coefficient values respectively. Before analyzing the permeability maps i.e. drawing ROI, intracranial 
volume was differentiated from skull and image background by thresholding signal intensity from 
recognized anatomical structures identified on DW and T2w images. Image analysis was performed on 
permeability coefficient maps using the software described above. The permeability map for each slice was 
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matched with DW image and ADC map to identify normal and injured regions. The lesion was identified on 
T2w and DW images as regions with long T2 relaxation time and low ADC values respectively. ROI was 
drawn manually by a single operator around regions with high signal intensity on the ipsilateral side and the 
same ROI was placed on the contralateral side. This step was repeated twice by the same operator in 
order to reduce intra-user bias. Analysis was repeated for the data sets obtained from vehicle and 
indomethacin-treated rats.  
 
Fluorometric Assay of Matrix Metalloproteinase-3 (MMP-3) Enzymatic Activity 
The activity of MMP-3 (stromelysin-1) was measured fluorometrically using a 5-FAM/QXL™520 
fluorescence resonance energy transfer (FRET) peptide (Cat. No. 60580; AnaSpec Inc., San Jose, CA). In 
the intact FRET peptide (5-FAM-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(QXL™520)-NH2), the 
fluorescence of 5-FAM (5-carboxyfluorescein) is quenched by QXL™520. Upon cleavage into two separate 
fragments by the MMP-3 present in the sample, the fluorescence of 5-FAM is recovered, and can be 
monitored at excitation/emission wavelengths of 490/520 nm. This peptide has been documented to be 
cleaved by only MMP-3 and MMP-12 (macrophage elastase), but not by other MMPs (Nagase et al., 1994). 
Rat brain homogenates containing 100 μg of protein (aliquot from the lysate prepared for zymography) 
were mixed with assay buffer (50 mM Tris-HCl pH 7.6, 200 mM NaCl, 5 mM CaCl2, 20 μM ZnSO4 and 
0.05% Brij-35) containing the FRET peptide (1 μM final concentration) to a final volume of 200 μl. The 
change in fluorescence (expressed as relative fluorescence units, RFU) was monitored at 5-min intervals 
for 1 h at room temperature using a luminescence spectrometer (PerkinElmer Instruments, Model LS55; 
Buckinghamshire, UK) attached to a workstation running FL WinLab software.  
 
Measurement of Reduced Glutathione (GSH)  
Levels of GSH were determined in rat brain homogenates using the monochlorobimane (MCB) method 
(Kamencic et al., 2000). MCB binds to GSH through interaction with glutathione-S-transferase (GST) to 
form a stable fluorescent adduct (MCB-GSH), allowing determination of GSH levels through fluorescent 
intensity of the MCB-GSH adduct. MCB has more selectivity for GSH over other thiols when compare with 
other bimanes, and was confirmed to react only with GSH (Fernandez-Checa and Kaplowitz, 1990). Brain 
homogenates (an aliquot from the homogenate prepared for zymography) containing 150 μg of protein 
were mixed, in duplicates, with the assay buffer (100 mM potassium phosphate buffer pH 6.5) containing 1 
U/ml of GST from equine liver (BioVision, Mountain View, CA) and 0.5 mM of MCB (Sigma-Aldrich, Saint 
Louis, MO) in a black 96-well plate. Samples were incubated in the dark for 30 min at 37°C. The 
fluorescent product formed was quantified using a spectrofluorometer (PerkinElmer Instruments, Model 
LS55; Buckinghamshire, UK) at excitation and emission wavelengths of 380 and 460 nm, respectively. 
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Fluorescence in each well was recorded for 3 sec, with a slit width of 5 nm and a cut-off set at 430 nm. 
Tissue GSH concentration was determined using a GSH standard curve and expressed as μg GSH/mg 
protein.  
 
Drug Treatment 
The COX inhibitors used in the present study included nimesulide (COX-2 selective), Valeroyl Salicylate 
(VAS; COX-1 selective) and indomethacin (non-selective). Drugs were obtained from Cayman Chemical 
(Ann Arbor, MI), and dissolved in 5% Cremophor® EL (Sigma-Aldrich, Saint Louis, MO) in saline for 
intraperitoneal (i.p.) administration. The doses used were 12, 20 and 10 mg/kg for nimesulide, VAS and 
indomethacin, respectively. Animals were treated with the COX inhibitors immediately after rhTNF-α 
injection and again at 8 h. These doses and treatment paradigms have been previously demonstrated to be 
effective in reducing PGE2 levels in the rodent brain (Paoletti et al., 1998; Candelario-Jalil et al., 2003c; 
Candelario-Jalil et al., 2007a). 
 
Statistical Analysis 
Data were analyzed using an unpaired t-test (2 groups) or one-way analysis of variance (ANOVA) with a 
post-hoc Student-Newman-Keuls test (multiple comparisons). In all statistical tests, differences were 
considered significant when p<0.05. Data are presented as mean ± standard error of the mean (S.E.M). 
Statistical analysis was performed using the program GraphPad Prism for Windows, Version 4.0 
(GraphPad Software Incorporated, San Diego, CA). 
 
 
RESULTS 
Inhibition of COX with indomethacin or VAS protects against rhTNF-α-induced BBB opening in the 
rat 
Using the 14C-sucrose method we found that the intracerebral injection of rhTNF-α produced a significant 
increase in the BBB opening at 24 h (Fig. 1). We then investigated the effects of the administration of 
different COX inhibitors on BBB permeability changes induced by rhTNF-α. Using selective inhibitors of 
each of the COX isozymes, we found that indomethacin and the COX-1 selective inhibitor VAS significantly 
(p<0.05) reduced the BBB opening in this animal model of neuroinflammation. However, the COX-2 
selective inhibitor nimesulide failed to significantly reduce rhTNF-α-induced BBB breakdown (Fig. 1).  
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Figure 2A shows a series of T2 weighted images and color-coded permeability coefficient maps for two 
representative rats: rhTNF-α plus vehicle (top row) and rhTNF-α plus indomethacin (bottom row). The T2 
weighted images demonstrated the lesion in relation to the anatomical detail in the rat brain. On the T2 
maps, a 12% reduction in T2 values was observed on the ipsilateral lesion side in the indomethacin treated 
animals compared to the rhTNF-α plus vehicle group. There was no significant reduction in Apparent 
Diffusion Coefficient (ADC) values in the indomethacin-treated group compared to the rhTNF-α plus vehicle 
group. Permeability coefficient color maps showed a reduction below 1.0 x 10-3 ml g-1 min-1 in the 
indomethacin treated group compared to over 3.0 x 10-3 ml g-1 min-1 in the rhTNF-α plus vehicle group 
(note the scale differences). Figure 2B shows a graph of mean permeability coefficient values in rhTNF-
α plus indomethacin group and rhTNF-α plus vehicle estimated using MRI. In the rhTNF-α plus vehicle 
group, the estimates in the ipsilateral and contralateral hemisphere were 5.47 ± 1.0 x 10-3 ml g-1 min-1 and 
0.38 ± 0.26 x 10-3 ml g-1 min-1, respectively. The permeability coefficient estimates in rhTNF-α plus 
indomethacin group were 0.41 ± 0.18 x 10-3 ml g-1 min-1 and 0.31 ± 0.18 x 10-3 ml g-1 min-1 in the ipsilateral 
and contralateral hemisphere, respectively. On applying one-way ANOVA test, there was a significant 
difference in permeability coefficient values between the groups. Furthermore, a significant difference 
(p<0.05) in the permeability coefficient values between the lesion and non lesion side in rhTNF-α plus 
vehicle rats was observed. However, the mean permeability coefficient estimates between the ipsilateral 
and contralateral side in rhTNF-α plus indomethacin rats were not significantly different. There was a 
significant (p<0.001) reduction observed in mean permeability coefficient values on the ipsilateral side in 
the indomethacin treated rats as compared to the untreated rats. 
 
The dramatic increase in MMP-9 activity following rhTNF-α injection is reduced by indomethacin 
treatment 
Intracerebral injection of 325 ng (5000 U) of rhTNF-α produced a significant increase in MMP-9 activity 
after 24 h compared with the saline-injected control, as revealed by gelatin zymography (Fig. 3A). 
Inhibition of COX with indomethacin produced a significant reduction in the gelatinolytic activity of MMP-9 
(Fig. 3B). No significant change in MMP-2 activity was observed in any of the treatment groups as 
compared to saline-injected animals.  
 
Indomethacin limits the induction of MMP-9 protein expression following intracerebral injection of 
rhTNF-α 
In our next experiments, we used immunoblotting to investigate the effect of indomethacin on the 
expression of MMP-9, MMP-2, COX-1 and COX-2 at 24 h following the injection of rhTNF-α into the rat 
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striatum. MMP-9 protein levels increased dramatically in rhTNF-α-injected rats (Fig. 4A). There was a 
significant reduction (p<0.05) in MMP-9 protein expression in animals injected with rhTNF-α and given 
indomethacin, as compared with vehicle-treated controls (Fig. 4A and 4B). In addition, the expression of 
COX-2 was significantly increased in the brain of rats injected with rhTNF-α when compared with saline 
injection (Fig. 4A and 4C). However, indomethacin treatment had no significant effect on rhTNF-α-
mediated COX-2 induction (Fig. 4C). Similar to the findings of the gelatin zymography analysis, rhTNF-
α did not produce any increase in MMP-2 protein expression (Fig. 4D), and indomethacin administration 
did not significantly affect MMP-2 protein levels (Fig. 4A and 4D). Furthermore, COX-1 expression was 
unaffected by rhTNF-α and did not change in rats administered indomethacin (Fig. 4 A and 4E). 
 
COX inhibition with indomethacin reduces rhTNF-α-induced MMP-3 protein expression and activity 
Since stromelysin-1 (MMP-3) contributes to BBB disruption during lipopolysaccharide (LPS)-induced 
neuroinflammation (Gurney et al., 2006b), we investigated the effects of COX inhibition with indomethacin 
on MMP-3 expression. Rat pro-MMP-3 was detected by Western blot in its glycosylated form at 
approximately 62 kDa. Results from this experiment indicated that pro-MMP-3 expression is dramatically 
induced by rhTNF-α when compared to saline (Fig. 5A and 5B). Very low levels of pro-MMP-3 were 
observed in saline-injected animals, and this was only observed when exposing the membrane to 
autoradiography film for longer periods of time (not shown). Treatment with indomethacin markedly 
reduced (p<0.05) pro-MMP-3 protein levels in comparison with TNF-α plus vehicle (Fig. 5A and 5B). 
Fluorescent enzymatic assay for MMP-3 activity showed a significant increase (p<0.01) in MMP-3 activity 
in the rhTNF-α plus vehicle group in relation to saline control, which was significantly (p<0.05) reduced by 
treatment with indomethacin (Fig. 5C).  
 
Cellular sources of MMP-9, MMP-3 and COX-2 following intracerebral injection of rhTNF-α 
Since intracerebral injection of rhTNF-α produced a significant increase in MMP-9, MMP-3 and COX-2 
levels, as revealed by the Western blot experiments (Figs. 4 and 5), we were interested in identifying the 
cellular source of these inducible proteins following rhTNF-α-mediated neuroinflammation. Double 
immunofluorescence labeling performed at 24 h showed that both, neurons (NeuN positive) and 
microglia/macrophages (OX-42 positive), were the cell types responsible for the enhanced MMP-9 
production after rhTNF-α injection (Fig. 6A). Very few GFAP-positive astrocytes were immunoreactive for 
MMP-9 in this model. Further inspection of these brain sections under a laser scanning confocal 
microscope confirmed that MMP-9-expressing cells were NeuN and OX-42 positive (Fig. 6A). Double 
immunolabeling for MMP-3 and each specific cellular marker was conducted in saline- and rhTNF-α-
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injected brains (treated with indomethacin or the vehicle). We observed colocalization of MMP-3 with 
NeuN- and OX-42-positive cells, but failed to find MMP-3 immunoreactivity in GFAP-positive astrocytes 
(Fig. 6B). A similar immunolabeling analysis was performed for COX-2. We observed COX-2 
immunoreactivity in neurons and microglia/macrophages (not shown). Compared to rhTNF-α-injected 
brains, saline-injected controls showed very few cells positive for either MMP-9, MMP-3 or COX-2 (not 
shown).  
 
Indomethacin prevented GSH depletion during rhTNF-α-mediated neuroinflammation 
COX activity is an important source of oxidative stress during neuroinflammation (Candelario-Jalil et al., 
2003b; Pepicelli et al., 2005; Akundi et al., 2005a). In order to investigate the effects of indomethacin 
treatment on endogenous antioxidant capacity following rhTNF-α, we measured GSH levels in brain 
homogenates prepared from saline, rhTNF-α plus vehicle, and rhTNF-α plus indomethacin groups. A 
significant reduction in GSH was found in the rhTNF-α plus vehicle group in relation to saline-injected 
animals and indomethacin reversed rhTNF-α-induced GSH depletion (Fig. 7).  
 
 
DISCUSSION  
Our results link MMPs to COX-mediated disruption of the BBB during TNF-α-induced neuroinflammation. 
We have demonstrated for the first time that pharmacological inhibition of COX with indomethacin protects 
against BBB disruption. Indomethacin significantly attenuated the activity and expression of MMP-9 and 
MMP-3, and prevented the loss of GSH following intracerebral injection of TNF-α.  
 
Other investigators have shown, in an in vitro model of the BBB that enhanced COX activity, with the 
concomitant increase in prostaglandin formation, is involved in TNF-α-mediated increase in permeability. 
Inhibition of COX activity with indomethacin or with the COX-2 selective inhibitor NS-398 prevented TNF-α-
induced changes in permeability (Mark et al., 2001a).  
 
A better understanding of the molecular mechanisms involved in TNF-α-mediated increase in MMPs could 
lead to the discovery of new potential targets amenable to pharmacological manipulation in order to limit 
BBB opening and brain edema in many neurological disorders. Earlier we showed that MMP-9 was 
induced by intracerebral injection of TNF-α (Rosenberg et al., 1995a). MMP blockade with the MMP 
inhibitor, BB-94 (Batimastat), prevented the BBB breakdown seen at 24 h following TNF-α injection 
(Rosenberg et al., 1995c), suggesting that enhanced MMP-9 activity is pivotal in BBB disruption. Present 
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data extend those findings by demonstrating that increased BBB permeability induced by TNF-α appears to 
be linked to the increase in MMP-9 and MMP-3 through a COX-dependent mechanism. Furthermore, we 
identified for the first time the cellular source of MMPs in this model of neuroinflammation. Double 
immunofluorescence and confocal microscopy showed that neurons and microglia/macrophages produce 
large amounts of MMP-9, COX-2 and MMP-3 following injection of TNF-α. The colocalization of MMP-9 
and MMP-3 in OX-42-positive cells around blood vessels is indicative of their role in BBB damage induced 
by TNF-α.  
 
The increased MMP-3 expression and activity observed after TNF-α represents the first in vivo evidence of 
the effect of this pro-inflammatory cytokine on MMP-3 levels in the injured brain. In addition, our data show 
that indomethacin treatment significantly reduces MMP-3 levels and enzymatic activity following TNF-α-
mediated neuroinflammatory events. These results are in line with an earlier in vitro study showing the 
protective efficacy of indomethacin against a TNF-α-induced increase in MMP-3 in fibroblasts (Morin et al., 
1999).  
 
Previous investigations have demonstrated that both MMP-3 and free radicals are involved in MMP-9 
activation during inflammatory events (Ogata et al., 1992; Gasche et al., 2001; Rosenberg et al., 2001; Gu 
et al., 2002). In addition, MMP-3 is able to cleave most components of the extracellular matrix (Wilhelm et 
al., 1987). Recently, we showed that MMP-3 is involved in BBB injury, neutrophil infiltration, and 
degradation of tight junction proteins following administration of LPS into the brain (Gurney et al., 2006a).  
 
Using gelatin zymography to measure MMP activity in TNF-α-injected brains only demonstrated latent 
forms of MMP-2 and MMP-9. Enzymatic activation of the gelatinases occurs at the cell surface and the 
activated species is quickly degraded resulting in low levels of active MMP in the tissue (Fridman et al., 
2003b). In addition, activation of MMP-9 can occur without removal of the inhibitory pro-peptide domain 
and consequently generate enzymatic activity in the absence of a noticeable change in molecular mass 
(Fridman et al., 2003a).  
 
Although the COX/PGE2 pathway is important in cancer and peripheral inflammation by enhancing MMP 
production, little is known about this pathway in neuroinflammation and brain injury. In an earlier study, a 
COX-2 selective inhibitor, NS-398, significantly reduced MMP-9 mRNA expression following radiation brain 
injury (Kyrkanides et al., 2002). Our finding that pharmacological inhibition of COX significantly reduced 
MMP-3 and MMP-9 protein expression and enzymatic activity in an in vivo model of brain injury could 
explain the efficacy of COX inhibitors in protecting against BBB disruption following cerebral ischemia 
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(Ting, 1990; Zuckerman et al., 1994; Candelario-Jalil et al., 2007f), bacterial meningitis (Kadurugamuwa et 
al., 1989), and against edema associated with brain tumors (Badie et al., 2003).  
 
The availability of selective inhibitors of the COX isozymes provides a powerful pharmacological tool to 
dissect the relative contribution of each isoform to the inflammatory process. By using this approach in the 
present study, we found that COX-1 seems to be more important than COX-2 in mediating TNF-α-induced 
BBB permeability changes. This finding is in contrast with results from our recent study in a rat model of 
focal cerebral ischemia, where COX-2 inhibition with nimesulide, but not COX-1 inhibition with VAS, 
potently reduced BBB breakdown in the ischemic cerebral cortex (Candelario-Jalil et al., 2007c). The 
apparent discrepancies among our studies, in terms of which COX isoform is playing the most important 
role in BBB damage, could be possibly explained by the different animal models employed (ischemia 
versus TNF-α). In addition, in the focal ischemic model we found that COX-2 inhibition failed to reduce BBB 
disruption in the striatum, and no significant increase in PGE2 levels were observed in the striatal 
homogenates prepared from ischemic animals as compared to sham controls (Candelario-Jalil et al., 
2007d). In our present study, TNF-α was injected intrastriatally, therefore we might speculate that the 
protective effect of COX-2 inhibition against BBB opening is region-specific. In an earlier study, we found 
that both COX isoforms contribute to oxidative damage and neurodegeneration in the hippocampus 
following a global cerebral ischemic event (Candelario-Jalil et al., 2003a). Thus, it seems that the 
contribution of each COX isozyme to the neuroinflammatory process depends on the type of injury, brain 
region under study, and possibly other unknown factors.  
 
It is interesting that, despite being upregulated by TNF-α, COX-2 does not seem to mediate BBB disruption 
induced by this pro-inflammatory cytokine. It is possible that it takes several hours for a catalytically active 
COX-2 protein to be present in the injected site. By then, most of the free arachidonic acid released by the 
TNF-α-induced PLA2 activity has been metabolized by COX-1. In this particular scenario following acute 
injection of TNF-α, arachidonic acid metabolism through COX-1 seems to play a greater role than through 
COX-2. This notion is supported by our findings that COX-1, but not COX-2, inhibition significantly limits 
TNF-α-mediated BBB breakdown. However, the observation that indomethacin confers more protection 
than the COX-1 inhibitor VAS may suggest that the relative small contribution of COX-2 should not be 
ignored.  
 
The differences we observed between ischemia- and TNF-α-induced BBB openings, in terms of which 
COX isoform is involved, may have important implications for the potential therapeutic use of COX 
Published in FINAL edited form as: 
Journal of Pharmacology and Experimental Therapeutics 323(2): 488-498 (2007)  
 16
inhibitors to limit the BBB opening in different clinical conditions. Non-selective COX inhibitors such as 
indomethacin might be useful in the management of BBB breakdown following inflammatory processes 
(e.g., bacterial meningitis), whereas in cerebral ischemia, a selective COX-2 inhibitor would be preferable 
(Candelario-Jalil et al., 2007e). Thus, the present findings herein shed more light into the specific role of 
COX in brain injury, and might have relevance for the potential use of COX inhibitors in the treatment of 
neurological disorders associated with BBB disruption. 
 
T2 maps provide a useful way of quantifying edema using MRI. A 12% reduction in T2 values from T2 
maps in the indomethacin treated group suggests that there was a decrease in edema due to drug 
treatment. This could probably be explained by the anti-inflammatory action of indomethacin. The reduction 
in permeability coefficient values due to indomethacin treatment was found to be statistically significant 
(p<0.05) and confirms the findings from the 14C-sucrose technique. This suggests that indomethacin may 
be working to reduce BBB leakage in the ipsilateral region and reiterates the BBB blocking effect of 
indomethacin and also suggests that indomethacin affects permeability on the ipsilateral side only and has 
no affect on the permeability in healthy tissue. 
 
In summary, the present study provides compelling evidence implicating COX activity in the TNF-α-induced 
BBB disruption. Inhibition of COX with indomethacin prevented BBB opening through a mechanism which 
possibly involves reduction in MMP-3 and MMP-9 expression/activity and prevention of the loss of 
endogenous antioxidant capacity. This investigation adds significant information on the molecular 
mechanisms underlying the protection seen with COX inhibitors against BBB damage in several models of 
brain injury. Our results show for the first time that BBB disruption during neuroinflammation can be 
significantly reduced by administration of COX inhibitors. We propose that modulation of COX in brain 
injury by COX inhibitors or agents modulating prostaglandin E2 formation/signaling may be useful in the 
clinical setting where the BBB is compromised by various pathologies. 
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Fig. 1. Effects of COX inhibitors on the uptake of 14C-sucrose into rat brain as a measure of BBB 
permeability. Rats received an intrastriatal injection of 5000 U (325 ng) of rhTNF-α and were treated 
with either nimesulide (COX-2 inhibitor; 12 mg/kg, i.p., n=6), Valeroyl salicylate (VAS; COX-1 
selective inhibitor; 20 mg/kg, i.p., n=6), indomethacin (non-selective COX inhibitor; 10 mg/kg, i.p., 
n=6) or the vehicle (5% Cremophor® EL in saline, n=12). A control group included rats injected 
intracerebrally with saline and treated with the vehicle (n=8). Drugs were given immediately after 
rhTNF-α injection and again at 8 h. After 24 h of the rhTNF-α injection, rats were given 10 μCi of 
14C-sucrose intravenously and sacrificed 10 min later. Samples from striatum and blood were 
collected, and brain sucrose uptake was calculated as a percentage of sucrose in brain to that in 
blood (Sucrose Space in %). Indomethacin and VAS significantly reduced rhTNF-α-induced BBB  
disruption. **p<0.001 with respect to saline. #p<0.01 and *p<0.05 with respect  TNF-α + vehicle. 
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Fig. 2. Panel A shows (a) T2 weighted image and (b) color coded permeability coefficient map for TNF-α + vehicle 
and TNF-α + indomethacin group. The anatomical T2 weighted images clearly demonstrate the extent of the lesion 
in both untreated and treated groups. However, visually the extent of the lesions appears to be limited in the treated 
group compared to the untreated group. Color-coded permeability maps demonstrate clearly the regions of high 
(arrow) and low permeability in treated and control rats. In the treated group, indomethacin affects permeability by 
blocking BBB leakage. Note the different color scales used for the permeability maps. Panel B: A plot of mean 
permeability coefficient estimates in TNF-α + vehicle (n=4) and TNF-α + indomethacin group (n=4) rats obtained 
using the MRI technique. The dashed line represents the upper limit of the range (0-1 x 10-3 ml/g-min) of 
permeability coefficient values in healthy tissue. Rats treated with indomethacin demonstrated a significant 
reduction in permeability coefficient values on the side of rhTNF-α injection as compared to the untreated rats. 
**p<0.05 with respect to vehicle ipsilateral. No significant difference was observed on the contralateral side 
between the control and treated rats. Bars represent mean ± S.E.M.
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Fig. 3. A: Representative gelatin zymogram showing the significant reduction by indomethacin of 
rhTNF-α-mediated increase in MMP-9 activity. Animals were injected in the striatum with either saline 
or 5000 U of rhTNF-α. Rats were treated with indomethacin (10 mg/kg, i.p., immediately after rhTNF-α
and again after 8 h; n=6). Another group of animals was treated with the vehicle agent (n=6). Protein 
samples were analyzed by gelatin zymography to detect the presence of gelatinases at 24 h after 
rhTNF-α injection. B: Quantitative estimation of gelatinolytic activity of MMP-9 by gelatin zymography 
analysis. Densitometric and statistical analyses show increases in the activity of MMP-9 following 
rhTNF-α injection and a significant reduction in animals administered indomethacin. No significant 
increase in MMP-2 activity was found after rhTNF-α microinjection. Densitometric analysis of lytic
zones at 72 kDa, corresponding to pro-MMP-2 activity, showed no significant changes among 
treatments (not shown). Bars represent mean ± S.E.M. of the 92-kDa band in arbitrary densitometric 
units. **p<0.05 with respect to saline. #p<0.05 with respect to the rhTNF-α plus vehicle group. 
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Fig. 4. Immunoblot analysis of protein levels of MMP-9, MMP-2, COX-2, COX-1 and actin in the rat brain after intracerebral injection 
of 325 ng of rhTNF-α (equivalent to 5000 U of TNF-α) or physiological saline. Animals were treated with the COX inhibitor 
indomethacin (10 mg/kg, i.p., immediately after rhTNF-α, and again after 8 h; n=6) or the vehicle agent (n=6). Protein extracts were 
prepared after 24 h of the injection with rhTNF-α, and subjected to SDS-PAGE followed by immunoblot analysis using specific 
antibodies. A: Representative Western blots for each protein in animals treated with saline, rhTNF-α plus vehicle, and rhTNF-α plus 
indomethacin. B-E: Quantitative densitometric analysis of relative protein expression normalized to actin loading control. 
Indomethacin significantly reduced MMP-9 expression induced by rhTNF-α. **p<0.05 with respect to MMP-9 expression in group 
injected with saline. #p<0.05 with respect to the rhTNF-α plus vehicle group. *p<0.05 with respect to COX-2 expression in saline-
injected brains. Bars represent mean ± S.E.M.
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Fig. 5. A: Western blot analysis of protein levels of pro-MMP-3 and actin in the rat brain after intracerebral injection of 325 ng of rhTNF-α 
or physiological saline. Animals were treated with the vehicle agent (n=6) or with the COX inhibitor indomethacin (10 mg/kg, i.p., 
immediately after rhTNF-α, and again after 8 h; n=6). Protein extracts were prepared after 24 h of the injection with rhTNF-α, and 
subjected to SDS-PAGE followed by immunoblot analysis using specific antibodies. Panel A shows representative Western blots for each 
protein in animals treated with saline, rhTNF-α plus vehicle, and rhTNF-α plus indomethacin. B: Quantitative densitometric analysis of 
relative protein expression normalized to actin loading control. Indomethacin significantly reduced rhTNF-α-induced pro-MMP-3 
expression. Only very faint bands for active MMP-3 (~45 kDa) were seen by Western blot. These bands appeared after a relatively long 
exposure of the blot to the autoradiography film. This hampered the accurate quantification of these bands using densitometry due to 
enhanced background. Similarly, saline-injected brains showed faint pro-MMP-3 expression, which was seen only after extended 
exposure of the blot to X-ray film. C: Analysis of MMP-3 activity using a fluorescence resonance energy transfer (FRET) peptide. 
Significant increase of MMP-3 relative activity was seen in rhTNF-α-injected brains as compared with saline injection. Treatment with the 
COX inhibitor indomethacin significantly reduced rhTNF-α-induced MMP-3 activity in the 24-h brain lysates. **p<0.05 with respect to 
saline. #p<0.01 with respect to the rhTNF-α plus vehicle group. Bars represent mean ± S.E.M.  
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A
B
Fig. 6. Double immunofluorescence and 
confocal microscopy analysis showing the 
cellular source of MMP-9 and MMP-3 following 
intracerebral injection of rhTNF-α. A: Z-stack 
showing MMP-9 positive cells colocalize with 
the neuronal marker NeuN and with OX-42 
positive cells (yellow color). Very few GFAP-
positive astrocytes expressed MMP-9 upon 
injection of TNF-α. B: Confocal microscopy (Z-
stack) confirmed the cellular source of MMP-3 
to be neurons and OX-42 positive cells 
(microglia/macrophages). Most 
microglia/macrophages expressing MMP-3 and 
MMP-9 were seen around blood vessels.  
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Fig. 7. Intracerebral injection of rhTNF-α produces a significant reduction in the levels of 
reduced glutathione (GSH) as compared to saline-injected control animals. Rats were 
treated with the vehicle agent (n=6) or with the COX inhibitor indomethacin (10 mg/kg, i.p., 
immediately after rhTNF-α, and again after 8 h; n=6). GSH levels were measured in brain 
homogenates after 24 h of the injection of rhTNF-α using the monochlorobimane (MCB) 
method. Homogenate extracts containing 150 μg of total protein were added to the assay 
buffer containing MCB and Glutathione-S-transferase and incubated for 30 min at 37°C in 
the dark. Formation of the MCB-GSH adduct was measured fluorometrically 
(Ex/Em=380/460 nm). Treatment with the COX inhibitor, indomethacin, prevented rhTNF-α-
induced depletion of GSH. **p<0.05 with respect to saline. #p<0.05 with respect to the 
rhTNF-α plus vehicle group. Bars represent mean ± S.E.M. 
